|
Post by kc on Aug 26, 2016 20:58:02 GMT -5
I have to agree. We are just gambling. we cannot wait further more than October. If scripts and sales #s aren't good, this will be worst than Titanic. Why? Because we will face a diluition or a R/S with a very very low price and stock (shareholders too) will visit The abysm. about shorts: 07/08/2016 (Was a sunday), i Was reading news and get an alert to My phone about MFRM (i had 500 shares and 5calls, Damn, just 5 unfortunately). Well, to resume, The alert Was about The Ikea of South-Africa buying MattresFirm for a premium of 105-110% vs Friday close. Stock was in a downtrend and closed at 29.90 ok Friday and They bought The company for 64usd per share. Friday at close, someone bought puts worths 400.000 usd. Well guys, i smile because i done good money with My shares and calls at The open on Monday, August 8th, but, i can assure you, that guy that bought puts for a total value of 400k and all The shorts caught with their pants down, were not happy as i was. why I'm telling you this? Because i prefer to be long and yes screw, but not to be short on a stock like MNKD. You never know when a news can be released (I'll Love Sunday night LOL). Odds we can go BK 95%, but that 5% in our favor, oh boy, could be Epic. op Biggest gamble on what should be a sure thing owning MannKind shares. That being said there have been many wake up calls on Pre-market Monday mornings like matress firm. Last year one of my favorites SIAL was bought out. Monsanto will be bought out in the next 30 days by Bayer AG. Running out of cash and bankruptcy is a serious threat to all of us. I hope we never see that day. Perhaps winning the motion to dismiss the class action suit will be a positive move forward as it proved out that Management was working hard but our partner Sanofi had already cut bait and screwed us. But that is for another thread as arbitration will bring us in some money in the future. With the court accepting mannkind's motion for dismissal helps clear the way to sell the company if the board decides it's time to insure that the future of the company is best served by being owned by a bigger Pharma. The board doesn't want a lowball fire sale but it also wants to make sure that shareholder equity is saved from a total wipeout. Nobody wins in a bankruptcy situation other than the attorneys and secured creditors. We know, the board knows that AFREZZA is too good to tie it to a bankrupt company. Brankruptcy only tarnishes the product further. It would be best to sell the company to somebody who can make AFREZZA the blockbuster insulin we know it can be.
|
|
|
Post by kingedxxxxx on Aug 26, 2016 21:22:39 GMT -5
With reports of docs getting new sample packs this week, I'm not sure why anyone is buying shares this week. You both said it, there probably won't be a big shift until October. It'd also be a bad thing if we don't see spikes once October comes. The reps either aren't hungry enough (doubtful) or the system is still broken and docs either aren't prescribing or spirometry, insurance, P.As (Mannkind cares should eliminate this one). Really, with how well this engine appears to be oiled right now, the only impediment would be patients/docs. Insurance coverage is greatly improving and spirometry shouldn't be that big of a deal if the patient really wants the medication. I want to say October will give us all the information we want to see, if not mid to late September. There should be jumps in scripts from now til then if things are going well. I'm going to hold out until mid-late September to add more if I add at all. The shorts haven't relented yet, they won't until they have to. They're doubling down on us going bankrupt. I'll let them drive the price lower before I add more, especially if we reverse split and dilute. They'll just do it all over again until there is reason not to. It's likely I could add shares again at $2 instead of buying now and have them worth $5 or so, depending on how much we invert. At least you are playing a wait and see. Crazy to try to add when stock is dropping miserably. Buying once scripts are increasing and showing some kind of stable improvement is the right time to consider buying/adding. That being said, I personally believe the game is over for MannKind and believe that chance of BK is at least 80%.
My reasoning falls on the hard facts that scripts are almost nothing. With the exposure Afrezza already had in the diabetic community and the number that have already tried it considering that the samples were not even counted in the new scripts, the number of refills is so low it is highly alarming. Why are not at least 50-75% of those trying Afrezza staying on it? It sure looks like the product is not performing for whatever reason.
I do believe there will be a small spike in scripts due to this relaunch, but there better be a very high rate of refills that support Afrezza is actually working for those patients. Right now, without any improvement, speculators are on the short side and longs are exiting trying to salvage at least part of their investment.
|
|
|
Post by op2778 on Aug 26, 2016 21:56:09 GMT -5
Looks like you are doing a little bit of soft bash saying that refil rate it's too small. That said, we will know soon If rate will increase or not. We are asking too much to 2.0 MNKD. Obviously they have done a lot of effort and we all want them to win this battle.
They have less than 2months working on that. At least end of year is needed to see If things turned out good or not. Yes, I'm aware that sales need to pick up and by big numbers, but, if scripts (and refil) will show a increasing rate, we could be safe.
In less that 3month we will know The story. op
|
|
|
Post by mnholdem on Aug 29, 2016 7:52:09 GMT -5
|
|
|
Post by kball on Aug 29, 2016 8:00:23 GMT -5
Coincidentally also an exact replica of my small intestine (the 2nd one)
|
|
|
Post by BlueCat on Aug 29, 2016 14:07:30 GMT -5
Coincidentally also an exact replica of my small intestine (the 2nd one) The walking path I now take whilst muttering to myself about my brokerage account. Going back into the right direx in the end is just happenstance.
|
|
|
Post by MnkdWASmyRtrmntPlan on Aug 29, 2016 15:12:05 GMT -5
How about ... Mannkind stock price chart between now and the end of the year )
|
|
|
Post by jurystillout on Aug 29, 2016 15:17:44 GMT -5
Unfortunately, MNKD does not resemble either one of these
|
|
|
Post by minnlearner on Aug 29, 2016 16:22:19 GMT -5
from your post to god's ear...
|
|
|
Post by MnkdWASmyRtrmntPlan on Aug 29, 2016 16:39:31 GMT -5
Unfortunately, MNKD does not resemble either one of these
it doesn't resemble them ... YET!
|
|
|
Post by factspls88 on Aug 29, 2016 16:42:40 GMT -5
Unfortunately the arrow is at the other end of the squiggle for Mannkind.
|
|
|
Post by mnholdem on Aug 29, 2016 18:43:56 GMT -5
|
|
|
Post by kingedxxxxx on Sept 2, 2016 21:31:01 GMT -5
Looks like you are doing a little bit of soft bash saying that refil rate it's too small. That said, we will know soon If rate will increase or not. We are asking too much to 2.0 MNKD. Obviously they have done a lot of effort and we all want them to win this battle. They have less than 2months working on that. At least end of year is needed to see If things turned out good or not. Yes, I'm aware that sales need to pick up and by big numbers, but, if scripts (and refil) will show a increasing rate, we could be safe. In less that 3month we will know The story Sorry to take so long to respond. Busy week.
Only trying to speak to the reality of the situation. Just spent some time to look at script counts over the past year. It is ugly. Very ugly. There are no more excuses. If Afrezza was a wonder drug, the diabetics would be demanding it. Word would be travelling like wildfire through social media. Doctors would be demanding it or at least wanting to know more to prescribe it. And, those using it would not quickly abandon the product. Something is horribly wrong and it is more than insurance and label issues. Sanofi ran from Afrezza as soon as they had the opportunity. They realized that this was not going to end well and limited their losses.
Those that have been long this stock for some time have been brainwashed by management and other long shareholders. You need to be able to step outside of MannKind and look in from a neutral position. Once script counts did not start popping in past several weeks now that MannKind is taking it upon themselves to try again, the market is finally realizing that this company is going to fail. At best, they will reorganize if they can present a plan that shows that they have some other viable product in the pipeline. Afrezza will be done. Regardless, shareholders will be left with nothing or close to nothing.
The only real friend you have out there is you. Take a long, hard look at the pros and cons and make a list. You will notice that there is only maybe a couple of things on the pro side and everything else is a con. This stock has been a sell since before the end of this year when scripts stopped growing. I hope many get out of this with their shirts on their back and did not invest too much of their hard earned money here.
|
|
|
Post by mnholdem on Sept 2, 2016 21:37:39 GMT -5
|
|
|
Post by kingedxxxxx on Sept 2, 2016 21:47:07 GMT -5
You're breaking my heart.
If you knew my posting history on Yahoo, you may consider otherwise. I am more of a PRO than a CON.
|
|